Ceftriaxone Sodium
Antibiotic
View Brand Names (11)Dose and dosage
10 mg/kg q24h IM/IV for 3-5 days
10 mg/kg q24h IM/IV for 3-5 days
For susceptible infections:
a) 25–50 mg/kg q12h IV or IM.Excellent CSF and bone penetration; expensive.
b) 20 mg/kg IV q12h
a) For meningitis/borreliosis: 15–50 mg/kg IV or IM q12h for 4–14 days
For preoperative/intraoperative use: 25 mg/kg IM or IV one time
For skin, genitourinary infections: 25 mg/kg IM once daily (q24h) for 7–14 days
b) For infectious endocarditis and documented resistance against or other contraindications for fluoroquinolones and aminoglycosides in dogs: 20
mg/kg IV q12h
c) 15–50 mg/kg (route not specified) once daily.
For systemic infections:
a) 25–50 mg/kg IV, IM or Intraosseous q12h as long as necessary (Greene & Watson 1998)
Ceftriaxone sodium is a 3rd generation cephalosporin antibiotic active against a variety of gram-positive and gram-negative bacteria and like other cephalosporins inhibits bacteria cell wall synthesis, is usually bactericidal and is a timedependent antibiotic.
The third generation cephalosporins retain the gram-positive activity of the first and second-generation agents, but, have much expanded gram-negative activity. As with the 2nd generation agents, enough variability exists with individual bacterial sensitivities that susceptibility testing is necessary for most bacteria. Because of the excellent gram-negative coverage of these agents and when compared to the aminoglycosides and their significantly less toxic potential, they have been used on an increasing basis in veterinary medicine.
AMINOGLYCOSIDES/NEPHROTOXIC DRUGS: The concurrent use of parenteral aminoglycosides or other nephrotoxic drugs (e.g., amphotericin B) with cephalosporins is somewhat controversial. Potentially, cephalosporins could cause additive nephrotoxicity when used with these drugs, but this interaction has only been well documented with cephaloridine (no longer marketed). In vitro studies have demonstrated that cephalosporins can have synergistic or additive activity against certain bacteria when used with aminoglycosides.
CALCIUM: Concomitant use with calcium containing solutions have caused fatal calcium-ceftriaxone precipitates in lungs and kidneys of neonatal humans. Do not mix with calcium or administer calcium-containing solutions or products within 48 hours of ceftriaxone administration.
Category B